Eucalyptus Oil

證據等級: L5

預測適應症: 10 個

Eucalyptus Oil: From Traditional Topical Analgesic to Osteoarthritis

One-Sentence Summary

Eucalyptus oil is a naturally derived botanical product traditionally used as a topical analgesic, antiseptic, and inhalant for respiratory symptoms — with no formally registered indications in Australia. The TxGNN model predicts it may be effective for Osteoarthritis, with 1 clinical trial and 3 publications currently supporting this direction for the primary indication, alongside broader anti-inflammatory mechanistic evidence from rheumatoid arthritis literature.

Quick Overview

Item	Content
Original Indication	No formally approved indication; traditionally used for topical analgesia and respiratory relief
Predicted New Indication	Osteoarthritis
TxGNN Prediction Score	98.48%
Evidence Level	L3
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Eucalyptus oil’s primary active constituent is Eucalyptol (1,8-Cineole), a monoterpene oxide with well-characterised anti-inflammatory and analgesic properties. Mechanistically, Eucalyptol suppresses the NF-κB signalling pathway, downregulates pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, and modulates TRPA1/TRPV1 pain receptors — all pathways centrally implicated in osteoarthritic joint pain and synovial inflammation. Transcutaneous absorption of topically applied eucalyptus oil can achieve local concentrations sufficient to dampen synovial inflammation at the joint.

Osteoarthritis is characterised by a progressive cycle of cartilage degradation, subchondral bone remodelling, and synovial inflammatory flares driven by the same cytokine networks that Eucalyptol inhibits. This mechanistic overlap provides a biologically plausible rationale for the TxGNN prediction. Supportive evidence from aromatherapy and herbal combination studies (e.g., Elmore Oil, which contains eucalyptus oil as a key component) suggests symptomatic benefit in arthritic conditions, though direct attribution to the eucalyptus oil component alone requires further investigation.

It is worth noting that the same mechanistic pathway also underpins the predicted link to rheumatoid arthritis (rank 2, TxGNN score 98.28%), where preclinical in vivo data using a Complete Freund’s adjuvant model and clinical inhalation studies both show meaningful anti-inflammatory effects. This convergence across two major arthritis subtypes strengthens the plausibility of the arthritis-related predictions as a whole.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01684371	N/A (Pilot)	Completed	60	Double-blind, placebo-controlled, crossover trial of topical Elmore Oil (a herbal combination containing eucalyptus oil, tea tree oil, olive oil, and vanilla) for osteoarthritis symptom relief. The formulation was reported to have anti-inflammatory properties. Note: this tests a multi-ingredient product; results cannot be directly attributed to eucalyptus oil alone.

Note: No ANZCTR-registered trials were identified for this drug-indication pair.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15778570	2005	Clinical Observational / Quasi-experimental	Taehan Kanho Hakhoe chi	Aromatherapy (including eucalyptus-containing blends) demonstrated significant effects on pain reduction, depression, and life satisfaction in arthritis patients.
38409718	2024	Pharmaceutical Formulation Study	Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry	Development of a celecoxib emulgel incorporating natural oils (including eucalyptus oil as an excipient/penetration enhancer) for osteoarthritis and rheumatoid arthritis; supports the topical delivery concept.
37111672	2023	Review	Pharmaceutics	Nanoemulgel systems for topical anti-inflammatory delivery; eucalyptus oil referenced as a permeation enhancer in transdermal formulations for inflammatory conditions.

Australia Market Information

Eucalyptus oil (DrugBank ID: DB11114) currently has no ARTG registrations in Australia. It is not listed as a marketed therapeutic good with the TGA. Any future development pathway would require a new registration or listing application under TGA legislation.

Safety Considerations

Detailed safety data (including product warnings, contraindications, and drug interactions) are not available in the current Evidence Pack.

Please refer to the TGA-approved Product Information (PI) and the TGA’s complementary medicine guidelines for safety information. Clinicians should note that undiluted eucalyptus oil is toxic if ingested and must not be applied near the face of infants or young children. Potential for CYP2B6/CYP3A4 metabolic interactions warrants evaluation before formal clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for eucalyptus oil in osteoarthritis is biologically plausible and supported by observational-level clinical data and preclinical studies, but the current evidence does not yet meet the standard required for a formal repurposing decision — the only completed trial used a multi-ingredient combination product rather than eucalyptus oil as a standalone agent, and eucalyptus oil has no current TGA registration in Australia.

To proceed, the following is needed:

Standalone clinical trial data: A well-controlled trial isolating the effect of eucalyptus oil (or purified Eucalyptol/1,8-Cineole) in osteoarthritis patients, separate from combination herbal formulations
Dose-finding and pharmacokinetic studies: Establish effective topical concentrations and transdermal absorption parameters in a human model
Safety data package: Obtain formal product warnings, contraindications, and drug interaction data (DrugBank API query recommended as a first step)
TGA regulatory pathway assessment: Determine whether the product would be classified as a listed complementary medicine, registered medicine, or therapeutic device, and identify applicable TGA submission requirements
MOA documentation: Formal mechanism of action characterisation (e.g., from DrugBank or primary pharmacology literature) to support a regulatory dossier
YMYL disclaimer: Any public-facing materials must include the statement: “These predictions are for research purposes only and do not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application.”
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.